253 related articles for article (PubMed ID: 7577096)
41. Dose escalation of amifostine for radioprotection during pelvic accelerated radiotherapy.
Koukourakis MI; Kyrgias G; Panteliadou M; Papadopoulou A; Tsiarkatsi M; Papachristou E; Bebeli M
Am J Clin Oncol; 2013 Aug; 36(4):338-43. PubMed ID: 22643562
[TBL] [Abstract][Full Text] [Related]
42. The potential role of amifostine in the treatment of carcinoma of the uterine cervix: a review.
Small W
Semin Radiat Oncol; 2002 Jan; 12(1 Suppl 1):68-74. PubMed ID: 11917288
[TBL] [Abstract][Full Text] [Related]
43. Study of cisplatin-vinblastine plus amifostine in patients with locally advanced or metastatic non-small cell lung cancer.
Thongprasert S; Chewaskulyong B
J Med Assoc Thai; 2004 Oct; 87(10):1162-7. PubMed ID: 15560691
[TBL] [Abstract][Full Text] [Related]
44. A Phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma: an Eastern Cooperative Oncology Group Study (E8188).
Gradishar WJ; Stephenson P; Glover DJ; Neuberg DS; Moore MR; Windschitl HE; Piel I; Abeloff MD
Cancer; 2001 Nov; 92(10):2517-22. PubMed ID: 11745184
[TBL] [Abstract][Full Text] [Related]
45. Clinical status and optimal use of amifostine.
Capizzi RL
Oncology (Williston Park); 1999 Jan; 13(1):47-59; discussion 63, 67. PubMed ID: 10027198
[TBL] [Abstract][Full Text] [Related]
46. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants.
Hensley ML; Hagerty KL; Kewalramani T; Green DM; Meropol NJ; Wasserman TH; Cohen GI; Emami B; Gradishar WJ; Mitchell RB; Thigpen JT; Trotti A; von Hoff D; Schuchter LM
J Clin Oncol; 2009 Jan; 27(1):127-45. PubMed ID: 19018081
[TBL] [Abstract][Full Text] [Related]
47. Amifostine in chemoradiation therapy for non-small cell lung cancer: review of experience and design of a phase II trial assessing subcutaneous and intravenous bolus administration.
Werner-Wasik M; Langer C; Movsas B
Semin Oncol; 2005 Apr; 32(2 Suppl 3):S105-8. PubMed ID: 16015544
[TBL] [Abstract][Full Text] [Related]
48. Proceedings of the Fourth International Cytoprotection Investigators' Congress. May 2004. Philadelphia, Pennsylvania, USA.
Semin Oncol; 2004 Dec; 31(6 Suppl 18):1-73. PubMed ID: 15801121
[No Abstract] [Full Text] [Related]
49. Pharmacologic normal tissue protection in clinical radiation oncology: focus on amifostine.
Mell LK; Movsas B
Expert Opin Drug Metab Toxicol; 2008 Oct; 4(10):1341-50. PubMed ID: 18798703
[TBL] [Abstract][Full Text] [Related]
50. Amifostine protects against cisplatin-induced nephrotoxicity in a child with medulloblastoma.
Hayek M; Srinivasan A
Pediatr Hematol Oncol; 2003; 20(3):253-6. PubMed ID: 12637222
[No Abstract] [Full Text] [Related]
51. Phase II evaluation of amifostine as an esophageal mucosal protectant in the treatment of limited-stage small cell lung cancer with chemotherapy and twice-daily radiation.
Arquette M; Wasserman T; Govindan R; Garfield D; Senzer N; Gillenwater H; Socinski M
Semin Radiat Oncol; 2002 Jan; 12(1 Suppl 1):59-61. PubMed ID: 11917286
[TBL] [Abstract][Full Text] [Related]
52. [Cytoprotective effect of Amifostine in the combined chemotherapy of advanced ovarian carcinoma].
Nagy P; Kádasi L
Orv Hetil; 2000 Sep; 141(37):2027-30. PubMed ID: 11037611
[TBL] [Abstract][Full Text] [Related]
53. Effect of amifostine on survival among patients treated with radiotherapy: a meta-analysis of individual patient data.
Bourhis J; Blanchard P; Maillard E; Brizel DM; Movsas B; Buentzel J; Langendijk JA; Komaki R; Swan Leong S; Levendag P; Pignon JP
J Clin Oncol; 2011 Jun; 29(18):2590-7. PubMed ID: 21576630
[TBL] [Abstract][Full Text] [Related]
54. Amifostine for protection from antineoplastic drug toxicity.
Foster-Nora JA; Siden R
Am J Health Syst Pharm; 1997 Apr; 54(7):787-800. PubMed ID: 9099346
[TBL] [Abstract][Full Text] [Related]
55. Amifostine, cisplatin, and vinblastine in metastatic non-small-cell lung cancer: a report of high response rates and prolonged survival.
Schiller JH; Storer B; Berlin J; Wittenkeller J; Larson M; Pharo L; Larson M; Berry W
J Clin Oncol; 1996 Jun; 14(6):1913-21. PubMed ID: 8656260
[TBL] [Abstract][Full Text] [Related]
56. [Amifostine otoprotection to cisplatin ototoxicity: a guinea pig study using otoacoustic emission distortion products (DPOEA) and scanning electron microscopy].
Hyppolito MA; de Oliveira AA; Lessa RM; Rossato M
Braz J Otorhinolaryngol; 2005; 71(3):268-73. PubMed ID: 16446928
[TBL] [Abstract][Full Text] [Related]
57. Chemoprotection in anticancer therapy: the emerging role of amifostine (WR-2721).
Kurbacher CM; Mallmann PK
Anticancer Res; 1998; 18(3C):2203-10. PubMed ID: 9703784
[TBL] [Abstract][Full Text] [Related]
58. Amifostine cytoprotection with chemotherapy for advanced ovarian carcinoma.
Rose PG
Semin Oncol; 1996 Aug; 23(4 Suppl 8):83-9. PubMed ID: 8783673
[TBL] [Abstract][Full Text] [Related]
59. Amifostine reduces side effects and improves complete response rate during radiotherapy: results of a meta-analysis.
Sasse AD; Clark LG; Sasse EC; Clark OA
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(3):784-91. PubMed ID: 16198504
[TBL] [Abstract][Full Text] [Related]
60. Radioprotective effect of amifostine in radiation pneumonitis.
Choi NC
Semin Oncol; 2003 Dec; 30(6 Suppl 18):10-7. PubMed ID: 14727236
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
